Abstract
The time course and duration of action of drugs used in cancer chemotherapy are greatly influenced by the molecular and biochemical properties of enzymes associated with their metabolism. Variation in the response of individual patients to cancer chemotherapeutic agents is in large measure due to genetic and environmental factors that impinge on specific enzymes belonging to the two major classes of drug metabolizing enzymes. Current knowledge of the molecular biology and biochemistry of phase I drug metabolizing enzymes (cytochrome P450, flavin-containing and xanthine oxidases, NADPH quinone reductase, and aldehyde and dihydropyridine dehydrogenases), and phase II enzymes (glucuronosyl-, sulfo-, N-acetyl-, and glutathione transferases, and hydrolases) is reviewed briefly. Advances in understanding genetic and environmental factors that influence activities of phase I and phase II pathways of drug metabolism are discussed in the first sections of this review followed by a consideration of the influence of drug metabolism on the actions of agents currently used in the treatment of cancer. Emphasis is given to drugs that have recently been introduced into the armamentarium of cancer chemotherapy including inhibitors of chromatin function, target-based inhibitors of signal transduction and cyclin-dependent kinases, and angiogenesis inhibitors acting on metalloproteinases, epithelial cell growth, angiogenesis stimulation, and endothelial-specific integrins.
Keywords: Cancer Drug Design, cancer chemotherapy, NADPH quinone reductase, chromatin function, angiogenesis stimulation, antineoplastic, cynomolgus monkeys, Genetic Polymorphism, nutritional impairment, Cytochrome P450, fish malodor syndrome, Xanthine oxidase, Eniluracil, blood-brain barrier, Crigler-Najjar syndrome, DNA-binding drugs, BLM-hydrolase, Exatecan mesylate, Etoposide and teniposide, Matrix Metalloproteinases
Current Cancer Drug Targets
Title: Challenges of Cancer Drug Design A Drug Metabolism Perspective
Volume: 1 Issue: 1
Author(s): R. I. Sanchez, S. Mesia-Vela and F. C. Kauffman
Affiliation:
Keywords: Cancer Drug Design, cancer chemotherapy, NADPH quinone reductase, chromatin function, angiogenesis stimulation, antineoplastic, cynomolgus monkeys, Genetic Polymorphism, nutritional impairment, Cytochrome P450, fish malodor syndrome, Xanthine oxidase, Eniluracil, blood-brain barrier, Crigler-Najjar syndrome, DNA-binding drugs, BLM-hydrolase, Exatecan mesylate, Etoposide and teniposide, Matrix Metalloproteinases
Abstract: The time course and duration of action of drugs used in cancer chemotherapy are greatly influenced by the molecular and biochemical properties of enzymes associated with their metabolism. Variation in the response of individual patients to cancer chemotherapeutic agents is in large measure due to genetic and environmental factors that impinge on specific enzymes belonging to the two major classes of drug metabolizing enzymes. Current knowledge of the molecular biology and biochemistry of phase I drug metabolizing enzymes (cytochrome P450, flavin-containing and xanthine oxidases, NADPH quinone reductase, and aldehyde and dihydropyridine dehydrogenases), and phase II enzymes (glucuronosyl-, sulfo-, N-acetyl-, and glutathione transferases, and hydrolases) is reviewed briefly. Advances in understanding genetic and environmental factors that influence activities of phase I and phase II pathways of drug metabolism are discussed in the first sections of this review followed by a consideration of the influence of drug metabolism on the actions of agents currently used in the treatment of cancer. Emphasis is given to drugs that have recently been introduced into the armamentarium of cancer chemotherapy including inhibitors of chromatin function, target-based inhibitors of signal transduction and cyclin-dependent kinases, and angiogenesis inhibitors acting on metalloproteinases, epithelial cell growth, angiogenesis stimulation, and endothelial-specific integrins.
Export Options
About this article
Cite this article as:
Sanchez I. R., Mesia-Vela S. and Kauffman C. F., Challenges of Cancer Drug Design A Drug Metabolism Perspective, Current Cancer Drug Targets 2001; 1 (1) . https://dx.doi.org/10.2174/1568009013334296
DOI https://dx.doi.org/10.2174/1568009013334296 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of Performance of Two Wavelet Families Using GLCM Feature Extraction for Mammogram Classification of Breast Cancer
Recent Advances in Computer Science and Communications Is Cdc25 a Druggable Target?
Anti-Cancer Agents in Medicinal Chemistry Effect of Formulation Variables on the Preparation of Ibuprofen Loaded Polymeric Nanoparticles
Pharmaceutical Nanotechnology Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design UCLA’s Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology
Combinatorial Chemistry & High Throughput Screening Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Regenerative Medicine Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Dis-organizing Centrosomal Clusters: Specific Cancer Therapy for a Generic Spread?
Current Medicinal Chemistry Synthesis and Biological Evaluation of Quinazoline Derivatives as Potential Anticancer Agents (II)
Anti-Cancer Agents in Medicinal Chemistry New Dehydroepiandrosterone-triazole Derivatives Identified as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Enzyme in the Prostate
Current Enzyme Inhibition Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Antithrombin, an Important Inhibitor in Blood Clots
Current Topics in Medicinal Chemistry Naturally Occurring and Synthetic Imidazoles: Their Chemistry and Their Biological Activities
Current Medicinal Chemistry